In Israel, Evogene Ltd. announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud. The new model expands the existing capabilities of ChemPass AI, Evogene’s tech-engine for small molecule discovery and optimization, by addressing one of the core challenges faced by both the pharmaceutical […]
In Israel, Evogene Ltd. recently announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small […]
In Israel, Evogene Ltd. received a letter from the Nasdaq Stock Market LLC indicating that the company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the company’s closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days. The Nasdaq Stock Market Rules provide […]
